1. Introduction {#s0005}
===============

Cardiovascular disease (CVD) is the leading cause of mortality among women in developed countries ([@bb0045]). Many CVD risk factors have been identified such as abdominal obesity, physical inactivity, diabetes, hypertension and dyslipidemia ([@bb0045], [@bb0160]). Cardiorespiratory fitness (hereafter "fitness") as well as physical activity levels are important and independent predictors of CVD, cardiac events and death among symptomatic and asymptomatic women ([@bb0050], [@bb0100], [@bb0040], [@bb0110]).

Fitness is a physiological attribute, defined by maximal oxygen uptake (VO~2~ max) measured using a maximal exercise test ([@bb0135]). A high fitness level estimated in metabolic equivalents (METs) has been defined as the 2 highest quintiles, which represents ≥ 8.5 METs for women between the ages of 50--59 years according to the Aerobics Center Longitudinal study ([@bb0180]). Furthermore, a low fitness value (\< 8.5 METs) was shown to be associated with a higher incidence of CVD events in men and women ([@bb0180]). Conversely, high fitness has been found to be inversely associated with the levels of visceral fat, insulin resistance, blood lipids and blood pressure as well as with the prevalence of the metabolic syndrome ([@bb0005], [@bb0030], [@bb0125], [@bb0120]) collectively reducing the risk of CVD.

Physical activity is defined as any body movement that increases energy expenditure, including both leisure time and non-leisure time activities ([@bb0015]). The 2011 Canadian Physical Activity Guidelines for adults recommends at least 150 min of moderate-to-vigorous intensity of aerobic physical activity per week ([@bb0185]). It has also been recommended to expend a minimum of 150 kcal/day or 1000 kcal/week of moderate-to-vigorous physical activity energy expenditure ([@bb0020]). Such physical activity levels recommendations have been demonstrated to be associated with increased health benefits, by reducing the risk of cardiometabolic risk factors and CVD in men and women ([@bb0110], [@bb0185], [@bb0200], [@bb0080], [@bb0155]).

Despite the fact that several studies having simultaneously investigated the association between fitness and physical activity levels and body composition, body fat distribution and cardiometabolic risk factors ([@bb0135], [@bb0080], [@bb0085], [@bb0150], [@bb0210]), controversy remains. While the majority reported that fitness is more strongly associated than physical activity levels with CVD and cardiometabolic risk factors ([@bb0135], [@bb0080], [@bb0150], [@bb0210]), one study suggested that physical activity level is as good as fitness to predict individual health ([@bb0085]). However, the majority of the studies used self-reported questionnaire for the assessment of physical activity levels ([@bb0135], [@bb0085], [@bb0150], [@bb0210]). Although, self-reported physical activity may be useful for ranking physical activity levels in large epidemiological studies, it lacks precision and validity ([@bb0080]) for longitudinal and prospective studies compared to the measurement of total volume of physical activity by accelerometry ([@bb0035]). Furthermore, accelerometer-derived physical activity measurements are more closely associated to cardiometabolic risk factors than that obtained from self-reported questionnaire ([@bb0035]).

The evidence supporting a relationship between fitness and/or physical activity levels and CVD risk factors has been well documented in the general population. Still, it is questionable if these relationships are the same in women going through the menopause transition. First, this is a period in a woman\'s life that results in a progressive decrease in estrogen ([@bb0140]), which is associated with an increase incidence and prevalence of cardiometabolic risk factors ([@bb0140]) and CVD ([@bb0170]). Second, we have previously reported, in the same cohort, that the time spent performing light physical activity have a greater effect on adiposity during menopause transition than moderate and/or vigorous physical activity ([@bb0165]). Third, the intensity of non-leisure time activities is lower than the relative intensity necessary to improve fitness ([@bb0015]).

Thus, the aim of the present study was to determine the influence of fitness and physical activity levels on cardiometabolic risk factors in non-obese women going through the menopause transition. We tested the following hypothesis: fitness and physical activity levels would be related with a favorable cardiometabolic risk factors in women followed through the menopause transition.

2. Methods {#s0010}
==========

2.1. Subjects {#s0015}
-------------

The study includes data from healthy premenopausal women aged between 47 and 55 years who participated in a 5-year longitudinal study from 2004 to 2009 (MONET Study: Montreal Ottawa New Emerging Team) ([@bb0010]). For the purpose of this secondary analysis, 66 out of the 91 participants who completed the original study were included, based on peak oxygen uptake (VO~2~ peak) and physical activity levels value availability at years 1 and 5. However, no differences were observed for baseline characteristics (data not shown) between those who completed the study and the sub-sample of participant used in the present analysis. Premenopausal women were included if they met the following criteria: (1) premenopausal status (two menstruations in the last three months, no increase in cycle irregularity in the 12 months preceding testing, and a plasma follicular-stimulating hormone level \< 30 IU/l as a mean of verification); (2) aged between 47 and 55 years; (3) no surgically-induced menopause; (4) non-smoker; (5) BMI between 20 and 29 kg/m^2^; and (6) reported weight stability (± 2 kg) for ≥ 6 months before enrolment in the study. Exclusion criteria were: (1) pregnant women or planned to become pregnant; (2) had medical problems that could have interfered with outcome variables including cardiovascular and/or metabolic diseases; (3) were taking oral contraceptives or hormone replacement therapy; (4) had high risk for hysterectomy; and (5) had a history of drug and/or alcohol abuse. Prior to inclusion in the study, written informed consent was obtained from each participant. This study was conducted according to the guidelines of the Declaration of Helsinki, and received the approval from the University of Ottawa and the Montfort Hospital Ethics committees.

2.2. Menopausal status {#s0020}
----------------------

Menopausal status was determined yearly by self-reported questionnaire about menstrual bleeding and its regularity and follicle-stimulating hormone (FSH) levels were measured annually during the early follicular phase to verify the menopausal status. Women were classified as premenopausal if they reported no change in menstrual cycle frequency and perimenopausal if they reported changes in menstrual frequency and/or amenorrhea for 3--11 months. Finally women were classified as postmenopausal based on their final menstrual period (FMP) and confirmed by 12 month of amenorrhea ([@bb0175]).

2.3. Anthropometric assessment {#s0025}
------------------------------

Body weight and height were measured with a BWB-800AS digital scale and a Tanita HR-100 height rod, respectively (Tanita Corporation of America, Inc. Arlington Heights, IL). Body mass index (BMI) was then calculated \[body weight kg/height (m^2^)\]. Waist circumference (mean of two measures) was determined using a Gulick tape at the mid-distance between the lowest rib and the iliac crest ([@bb0065]). Body composition (fat mass and lean body mass) and % body fat were measured using dual-energy X-ray absorptiometry (DEXA) (GE-LUNAR Prodigy module, GE Medical Systems, Madison, Wi, USA) as previously described ([@bb0010]).

2.4. Cardiorespiratory fitness {#s0030}
------------------------------

A graded progressive exercise test on the treadmill was performed to measure VO~2~ peak by indirect calorimetry. The progressive test consisted of 3-minute stages starting with a speed of 3.4 mph and a slope of 0% with an increasing workload to the point of participant exhaustion (speed increased to 4.0 mph by stage 6, 5.2 mph by stage 8 and 6.0 mph by stage 10; slope increased by 4% at every stage). Heart rate, blood pressure and the rate of perceived exertion (Borg scale) ([@bb0055]) were taken at rest and at the end of each stage during the test. Breath-by-breath samples of expired air were collected through a mouthpiece during the test, and measurements of VO~2~ and VCO~2~ were obtained using a Vmax 229 series metabolic cart (SensorMedics Corporation, Yorba Linda, CA). The indirect calorimetry unit was calibrated before each test according to the manufacturer\'s specifications.

After a brief warm up on the treadmill, women performed the exercise test. The test was terminated when at least 2 of the following criteria were achieved ([@bb0100]): 1) predicted maximal heart rate reached, 2) respiratory quotient \> 1.1, 3) VO~2~ remained stable or decreased with an increase in workload, or 4) rate of Borg-type scale reached ≥ 19. VO~2~ peak was considered as the highest 30 s average VO~2~ reached during the test.

2.5. Physical activity levels {#s0035}
-----------------------------

An accelerometer (Actical; Mini Mitter Co, Inc., Bend, OR) was used to measure physical activity levels in kcal/day and time spent in physical activity of various intensities (sedentary, light, moderate and vigorous) per week. Once a year, participants wore the accelerometer upon waking up and took it off just before going to bed for 7 consecutive days, as previously described ([@bb0010]). 24 h of continuous recording was performed by the accelerometers and time spent performing sedentary exercise was also considered when participants were not wearing the device (sleep time). Daily activity levels measured via acceleromety were found to be a good predictor of energy expenditure (r = 0.92--0.97) ([@bb0060]). The accelerometers used to measure physical activity energy expenditure in this study were also validated with the use of doubly labeled water measurements ([@bb0095]).

2.6. Resting blood pressure {#s0040}
---------------------------

Qualified research assistants measured supine resting blood pressure manually from the left arm after participants had been resting quietly for 5 min using a standard stethoscope and a mercury sphygmomanometer. For this measurement, an appropriate cuff size was selected for each participant based on arm circumference. Assessment of resting blood pressure was standardized according to the ([@bb9000]) SBP was considered as the first detectable Korotkoff sound (phase 1) and DBP was considered as the last detectable Korotkoff sound (phase 5) ([@bb0070]).

2.7. Blood sampling {#s0045}
-------------------

Blood samples were taken after a 12-h overnight fast. Plasma insulin concentrations were measured in duplicate by radioimmunoassay using ^125^I-labeled human insulin and a human insulin antiserum (Millipore, St. Charles, MO, USA). Plasma glucose levels were determined using spectrophotometric analysis after conversion of glucose to glucose-6-phosphate by hexokinase (Sigma-Aldrich Canada Ltd., Oakville, ON, CAN; Fisher Scientific Limited, Nepean, ON, CAN). Insulin resistance was estimated using the homeostasis model assessment \[HOMA-IR = (fasting glucose × fasting insulin)/22.5\]. Total cholesterol (TC), high-density-lipoproteins cholesterol (HDL-C), and triglycerides (TG) were analyzed using the Vitros 950 immunoassay analyzer (Ortho Clinical Diagnostics, Johnson & Johnson Company, Markham, ON, CAN) at a wavelength of 540 nm. TC, HDL-C, and TG were used in the Friedewald ([@bb0090]) formula to calculate low-density-lipoproteins cholesterol (LDL-C) concentration. Serum c-reactive protein (CRP), was assessed by immunonephelometry on an Image analyzer (Beckman-Coulter, Villepinte, France) with detection limits of 0.20 mg/l. Apolipoprotein B (apoB) was assessed by immunoturbidimetry (Architect, Abbott, Rungis, France) with detection limits of 0.03 g/l. All measures of blood profile presented a coefficient of variation of \< 15%.

2.8. Statistical analysis {#s0050}
-------------------------

Data are presented as means ± standard deviation. Variables were first checked for normality. Consequently, only TG and CRP were log-transformed to normalize the distribution. ANOVA was performed to compare fitness and physical activity levels between menopause status (premenopause, perimenopause and postmenopause), for the purpose of this analysis the database was transformed into cases as previously described ([@bb0010]). Pearsons\' correlations were performed to document the associations between the changes (year 5 - baseline) in fitness, physical activity levels and the changes observed in variables of interest. Participants were divided into groups based on their VO~2~ peak (\< 30.0 vs. ≥ 30.0 mlO~2~ kg^− 1^ min^− 1^) according to the high fitness (8.5 METs) classification for age and sex-specific estimated metabolic equivalent levels of fitness ([@bb0180]). Furthermore, we elected to use daily total volume of physical activity levels expressed in kcal/day. The latter has shown to be a better metric than time spent in various physical activity intensities because it incorporates the full continuum of physical activity intensities ([@bb0035]). Participants were therefore divided in two sub-group based on physical activity levels (\< 770.0 vs. ≥ 770.0 kcal/day). Three-way linear mixed model repeated measures analyses were used for determination of main effects on cardiometabolic risk factors (waist circumference, fasting plasma lipids, glucose and insulin levels, HOMA-IR score, CRP, apoB and resting systolic and diastolic blood pressure). Time (baseline and year 5) was considered as a *within*-*subject* factor; VO~2~ peak (low \< 30.0 vs. high ≥ 30.0 mlO~2~ kg^− 1^ min^− 1^) and physical activity levels (\< 770.0 vs. ≥ 770.0 kcal/day) were considered as *between*-*subject* factor. Results are expressed as the mean ± standard deviation. A *P* value ≤ 0.05 was considered as significant. SPSS 17.0 for windows (SPSS Inc. Chicago, IL, USA) was used to perform statistical analyses.

3. Results {#s0055}
==========

Participants\' characteristics are presented in [Table 1](#t0005){ref-type="table"}. At baseline, mean age of the participants was 49.8 ± 1.9 years (range: 47 to 54 years), and % body fat was 31.1 ± 7.0 (range: 18.2 to 41.7%). The mean VO~2~ peak was 33.6 ± 6.5 (range: 20.9 to 52.0 mlO~2~ kg^− 1^ min^− 1^) and daily physical activity levels was 829.9 ± 266.4 (range: 326.3 to 1904.7 kcal/day). All 66 women were premenopausal at year 1. By the end of year 5, 4 were still premenopausal (FSH: 26.5 ± 24.7 IU/l), 17 were perimenopausal (FSH: 48.6 ± 38.9 IU/l) and 46 had become postmenopausal (FSH: 85.2 ± 29.5 IU/l).

To analyze the effect of menopause transition on fitness and physical activity levels, the database was transformed into cases based on menopausal status ([@bb0010]). As a result, no significant differences were observed between menopause group (premenopause vs. perimenopause vs. postmenopause) for VO~2~ peak, and for physical activity levels ([Table 2](#t0010){ref-type="table"}).

Pearsons\' correlations between the changes (year 5 - baseline) in fitness, physical activity levels and the changes observed in cardiometabolic risk factors were preformed. As a result, only the change in physical activity levels showed significant negative association with apoB (*P* \< 0.05). No significant correlations were observed between changes in fitness and cardiometabolic risk factors ([Table 3](#t0015){ref-type="table"}).

Three-way linear mixed model repeated measures ([Table 4](#t0020){ref-type="table"}) were performed to document the main effect of time (baseline and year 5), fitness, and physical activity levels on cardiometabolic risk factors, in women going through the menopause transition. A significant effect of time was observed for various indices of cardiometabolic risk factors, indicating an overall increase over time, with the exception of fasting plasma glucose and CRP, which showed a decrease in time. Significant effect of fitness was also observed for waist circumference, fasting TG, insulin, HOMA-IR score, apoB and diastolic blood pressure. These variables were significantly lower in women with a VO~2~ peak ≥ 30.0 mlO~2~ kg^− 1^ min^− 1^ compared to women with a VO~2~ peak \< 30.0 mlO~2~ kg^− 1^ min^− 1^. Despite significant effect of physical activity level was observed for waist circumference and TG (\< 0.05) only the TG was lower in women with physical activity levels ≥ 770.0 Kcal/day. Finally, no fitness × physical activity levels interaction was observed for any variables of interest.

4. Discussion {#s0060}
=============

The present study determined the influence of objective measures of fitness and physical activity levels on cardiometabolic risk factors in non-obese premenopausal women going through menopause transition. According to the mixed model repeated measures, we found that fitness had independent effects on measures of waist circumference, fasting TG, insulin, HOMA-IR score, apoB and diastolic blood pressure. The results showed overall lower values in women with a high fitness. Physical activity levels, on the other hand, was negatively associated with apoB, however this observation no longer remained in the repeated measures analysis. In fact, physical activity did not have an independent impact on more favorable values of cardiometabolic risk factors compared to fitness. This suggests that fitness may have greater cardioprotective effects than physical activity levels in women transitioning to menopause. These findings further support existing studies ([@bb0135], [@bb0080], [@bb0150], [@bb0210]) that reported fitness as a stronger correlate of cardiometabolic risk factors, despite the use of accelerometers in this study for the measurement of physical activity levels compared to self-reported questionnaire. One study reported, in a sample of Chinese women aged 55 to 69, that both physical activity (self-reported questionnaire) and fitness were associated with the prevalence of the metabolic syndrome, adjusted for confounding variables ([@bb0210]). However, when physical activity was further adjusted for fitness, the association with metabolic syndrome was eliminated; when fitness was adjusted for physical activity, the association remained ([@bb0210]). Another study reported, in 53 men (68 ± 9 years) and 63 women (67 ± 7 years) that high fitness, independent of physical activity (measured by doubly labeled water and accelerometer), showed lower levels of fasting triglycerides, total cholesterol, TC/HDL-C, insulin and waist circumference (0.01 \> *P* \< 0.05) ([@bb0080]).

Overall, the results are in line with the classical knowledge that fit individuals have better CVD risk factors profile than unfit subjects ([@bb0105], [@bb0130], [@bb0190], [@bb0205]). However, even if higher values of cardiometabolic risk factors were observed in our women with lower fitness, the absolute values were still within normal ranges. This can be explained by the fact that this cohort is composed of healthy non-obese women with no major cardiometabolic complications. Also the participants\' mean waist circumference value is lower than the reported thresholds of 88.0 cm; which has been associated with an increased risk of cardiometabolic disturbance in women ([@bb0115]).

Even though physical activity levels was not a better correlate of cardiometabolic risk factors, it is known to be an important determinant of fitness ([@bb0120]). However, in the present study, we did not find a significant correlation between physical activity levels and fitness (data not shown). This supports the idea that these two phenotypes may act in an independent manner on various CVD risk factors ([@bb0080]) and could explain why we did not observe a fitness x physical activity levels interactions in the present study.

Finally, in healthy women, menopause *per se* was found to be associated with decrease in fitness through cardiopulmonary alterations affected by estrogen deficiency and a reduced level of nitric oxide ([@bb0145]). These alterations account partially for the impairment of endothelium-dependent vasodilation, preventing O~2~ flow to match the increase O~2~ requirement during exercise ([@bb0145]). Despite what has been reported in the previous study, no effect of the menopausal status was observed for fitness in the present sub-group as well as reported by our group for the whole MONET cohort ([@bb0010]). This is partly due to the fact that the participant remained fairly active, based on the absence of a significant change in physical activity levels between menopausal status, in this study, and during the 5 years follow-up, as reported elsewhere ([@bb0075]).

Our study presents some limitations. First, the population studied consisted of healthy women with a BMI \< 30 kg/m^2^. Therefore, our findings cannot be generalized to the whole population with a wide range of BMIs. Nonetheless, it is important to mention that 45% of the women aged between 40 and 59 years in the Canadian population present a normal BMI and 76% have a BMI \< 30 kg/m^2^. Second, we used data taken from year 1 and year 5, based on fitness and physical activity levels availability. Therefore we could not account for fitness and physical activity levels at every year and between the yearly testing sessions during the 5-year follow-up. Finally, because we worked with healthy premenopausal women at low risk for CVD, the duration of the follow-up might be insufficient to capture the magnitude of the effect of menopause transition on cardiometabolic risk factors. Despite these limitations, the well-characterized cohort of healthy non-obese (BMI \< 30 kg/m^2^) physically active women followed for 5 years strengthens the present study. We used indirect calorimetry and accelerometry, for the measurement of VO~2~ peak and physical activity levels respectively, which are valid and highly reproducible measure of these phenotype ([@bb0035], [@bb0095], [@bb0195]).

5. Conclusion {#s0065}
=============

The results of this study suggest that menopause does not have an impact on fitness and physical activity levels expressed in kcal/day. Furthermore, fitness was associated with more favorable values of cardiometabolic risk factors compared to physical activity levels in active non-obese premenopausal women transitioning to menopause.
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###### 

Anthropometric and cardiometabolic characteristics of premenopausal women (n = 66) at baseline (MONET study 2004--2009, Ottawa).

Table 1

  Variables                              Mean ± SD       Minimum   Maximum
  -------------------------------------- --------------- --------- ---------
  Age (yrs)                              49.8 ± 1.9      47        54
  Body mass index (kg/m^2^)              23.2 ± 2.4      19.3      28.7
  \% Body fat                            31.1 ± 7.0      18.2      41.7
  Fat mass (kg)                          19.0 ± 5.6      9.6       29.9
  Lean body mass (kg)                    38.9 ± 3.9      31.1      47.3
  Waist circumference (cm)               78.1 ± 7.1      62.2      93.7
  Triglycerides (mmol/l)                 0.84 ± 0.31     0.41      1.98
  Total cholesterol (mmol/l)             4.39 ± 0.69     3.05      6.23
  HDL-C (mmol/l)                         1.53 ± 0.33     0.81      2.29
  LDL-C (mmol/l)                         2.47 ± 0.65     1.33      4.25
  TC/HDL-C                               3.01 ± 0.79     1.78      5.40
  Fasting Glucose (mmol/l)               4.79 ± 0.38     3.80      5.70
  Fasting Insulin (uU/ml)                11.45 ± 4.02    5.03      32.07
  HOMA-IR                                2.45 ± 0.90     1.14      6.98
  CRP (mg/l)                             1.70 ± 1.90     0.20      10.40
  apoB (g/l)                             0.74            0.47      1.20
  VO~2~ peak (mlO~2~ kg^− 1^ min^− 1^)   33.6 ± 6.5      20.9      52.0
  Physical activity (kcal/day)           829.9 ± 266.4   326.3     1904.7

n: number of subjects (number differ because of missing data); SD: standard deviation; HDL-C: high-density lipoproteins cholesterol; LDL-C: low-density lipoproteins cholesterol; TC: total cholesterol; HOMA-IR: homeostasis model assessment; CRP: C-reactive protein; apoB: apolipoprotein B.

###### 

Comparison of fitness and physical activity levels between menopausal status (MONET study 2004--2009, Ottawa).

Table 2

  -----------------------------------------------------------------------------------------------
                                      Menopause status   *P* Value                       
  ----------------------------------- ------------------ --------------- --------------- --------
  n                                   66                 17              45              

  Fitness (mlO~2~ kg^− 1^ min^− 1^)   33.9 ± 6.3         33.9 ± 6.1      32.7 ± 6.6      = 0.56

  n                                   66                 15              41              

  Physical activity levels\           825.6 ± 266.7      849.0 ± 244.2   803.9 ± 256.6   = 0.81
  (kcal/day)                                                                             
  -----------------------------------------------------------------------------------------------

n: number of subjects. Results are expressed as mean ± standard deviation.

###### 

Relationships between 5-year changes of fitness, physical activity levels and changes in cardiometabolic risk profile in women transitioning from pre to post-menopausal (MONET study 2004--2009, Ottawa).

Table 3

                        Fitness   Physical activity levels
  --------------------- --------- ------------------------------------------
  n                     65        56
  Waist circumference   − 0.16    − 0.06
  n                     61        55
  Triglycerides         − 0.14    − 0.03
  Total cholesterol     − 0.13    − 0.06
  HDL-C                 0.09      0.16
  LDL-C                 − 0.18    − 0.26
  TC/HDL-C ratio        − 0.19    − 0.26
  Fasting glucose       − 0.06    − 0.01
  Fasting insulin       − 0.18    − 0.07
  HOMA-IR               − 0.19    − 0.06
  CRP                   − 0.02    − 0.24
  apoB                  0.01      − 0.38[⁎⁎](#tf0005){ref-type="table-fn"}
  n                     59        53
                                  
  *Blood pressure*                
  Systolic              − 0.05    0.25
  Diastolic             − 0.004   0.19

n: Number of subjects; HDL-C: high-density lipoproteins cholesterol; LDL-C: low-density lipoproteins cholesterol; TC: total cholesterol; HOMA-IR: homeostasis model assessment; CRP: c-reactive protein; apoB: apolipoprotein B. Triglycerides and CRP were log-converted for analysis.

*P* \< 0.01.

###### 

Cardiometabolic risk factors characteristics of women by time point, fitness (mlO~2~ kg^− 1^ min^− 1^) and physical activity levels (kcal/day) (MONET study 2004--2009, Ottawa).

Table 4

                               Fitness \< 30.0 Mean ± SD                      Fitness ≥ 30.0 Mean ± SD                       Physical activity levels \< 770.0 Mean ± SD    Physical activity levels ≥ 770.0 Mean ± SD     Independent effects (*P* value)                                                                                                                                      
  ---------------------------- ---------------------------------------------- ---------------------------------------------- ---------------------------------------------- ---------------------------------------------- --------------------------------- -------------- ---------------------------------------------- ---------------------------------------------- ---------- ---------- ----------
  n                            24                                             28                                             42                                             37                                             32                                23             34                                             33                                                                   
  Waist circumference (cm)     81.7 ± 6.6                                     82.5 ± 7.4                                     76.1 ± 6.5                                     74.3 ± 4.8                                     75.6 ± 6.9                        76.4 ± 6.7     80.5 ± 6.5                                     79.1 ± 7.7                                     NS         \< 0.001   \< 0.05
  n                            24                                             27                                             42                                             34                                             32                                24             34                                             30                                                                   
  Triglycerides (mmol/l)       0.96 ± 0.38[a](#tf0010){ref-type="table-fn"}   0.94 ± 0.38[b](#tf0015){ref-type="table-fn"}   0.76 ± 0.24                                    0.85 ± 0.36                                    0.89 ± 0.39                       1.01 ± 0.41    0.78 ± 0.20[c](#tf0020){ref-type="table-fn"}   0.77 ± 0.28^d^                                 NS         \< 0.05     \< 0.05
  Total cholesterol (mmol/l)   4.52 ± 0.69                                    5.02 ± 0.79                                    4.31 ± 0.69                                    4.87 ± 0.72                                    4.24 ± 0.60                       4.90 ± 0.77    4.53 ± 0.76                                    5.98 ± 0.74                                    \< 0.001   NS         NS
  HDL-C (mmol/l)               1.52 ± 0.40                                    1.68 ± 0.33                                    1.53 ± 0.29                                    1.73 ± 0.36                                    1.47 ± 0.32                       1.68 ± 0.37    1.58 ± 0.34                                    1.74 ± 0.33                                    \< 0.001   NS         NS
  LDL-C (mmol/l)               2.53 ± 0.73                                    2.87 ± 0.69                                    2.44 ± 0.61                                    2.75 ± 0.60                                    2.37 ± 0.53                       2.75 ± 0.62    2.57 ± 0.74                                    2.85 ± 0.67                                    \< 0.001   NS         NS
  TC/HDL-C                     3.19 ± 1.02                                    3.11 ± 0.84                                    2.90 ± 0.60                                    2.90 ± 0.60                                    3.01 ± 0.72                       3.01 ± 0.68    3.00 ± 0.85                                    2.97 ± 0.77                                    NS         NS         NS
  Fasting glucose (mmol/l)     4.86 ± 0.49                                    4.63 ± 0.44                                    4.75 ± 0.31                                    4.55 ± 0.36                                    4.76 ± 0.35                       4.57 ± 0.35    4.82 ± 0.42                                    4.60 ± 0.44                                    \< 0.001   NS         NS
  Fasting insulin (uU/ml)      13.2 ± 5.0                                     11.8 ± 2.9                                     10.5 ± 2.9                                     10.2 ± 2.8[e](#tf0030){ref-type="table-fn"}    11.6 ± 5.1                        10.7 ± 2.7     11.2 ± 2.7                                     11.0 ± 3.1[f](#tf0035){ref-type="table-fn"}    NS         \< 0.01    NS
  HOMA-IR                      2.86 ± 1.11                                    2.46 ± 0.66                                    2.21 ± 0.66                                    2.12 ± 0.55[g](#tf0040){ref-type="table-fn"}   2.48 ± 1.12                       2.20 ± 0.47    2.42 ± 0.64                                    2.34 ± 0.75[d](#tf0025){ref-type="table-fn"}   NS         \< 0.01    NS
  CRP (mg/l)                   2.02 ± 2.01                                    1.47 ± 1.52[h](#tf0045){ref-type="table-fn"}   1.51 ± 1.83^i^                                 0.99 ± 1.63[j](#tf0055){ref-type="table-fn"}   1.71 ± 1.97                       1.35 ± 1.98    1.69 ± 1.86[k](#tf0060){ref-type="table-fn"}   1.05 ± 1.08[k](#tf0060){ref-type="table-fn"}   \< 0.01    NS         NS
  apoB (g/l)                   0.78 ± 0.18                                    0.80 ± 0.19[h](#tf0045){ref-type="table-fn"}   0.72 ± 0.12[i](#tf0050){ref-type="table-fn"}   0.71 ± 0.18[j](#tf0055){ref-type="table-fn"}   0.74 ± 0.13                       0.73 ± 0.17    0.75 ± 0.16[k](#tf0060){ref-type="table-fn"}   0.76 ± 0.21[k](#tf0060){ref-type="table-fn"}   NS         \< 0.05    NS
  n                            24                                             27                                             42                                             33                                             32                                22             34                                             32                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                
  *Resting blood pressure*                                                                                                                                                                                                                                                                                                                                                                      
  Systolic (mmHg)              114.4 ± 9.6                                    119.9 ± 12.3                                   116.2 ± 11.6                                   119.1 ± 11.5                                   115.3 ± 11.6                      121.5 ± 12.1   115.8 ± 10.3                                   117.5 ± 11.3                                   NS         NS         NS
  Diastolic (mmHg)             75.4 ± 6.2                                     75.3 ± 7.4                                     71.6 ± 7.6                                     73.3 ± 7.4                                     71.9 ± 7.8                        75.6 ± 8.5     73.9 ± 6.8                                     73.9 ± 6.3                                     NS         \< 0.05    NS

PAEE: physical activity energy expenditure; N: number of subjects; HDL-C: high-density lipoproteins cholesterol; LDL-C: low-density lipoproteins cholesterol; TC: total cholesterol; HOMA-IR: homeostasis model assessment.

Linear mixed models repeated measures; Independent effect of time (within subject factor); Independent effect of fitness (between subject factor); Independent effect of PAEE (between subject factor).

Triglyceride and CRP were log-converted for statistical analysis and reconverted for presentation in table format.
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